Ever Supreme Bio Technology , Ltd Return on Equity

The latest ROE for 6712.TWO is 16.82%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Ever Supreme Bio Technology , Ltd's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, 6712.TWO currently prints 16.82% for ROE, while the sector average sits near -100.59%. That is roughly 116.7% above the sector mean. Large gaps often invite a closer look at Ever Supreme Bio Technology , Ltd's growth, margins, and balance sheet.

Return on Equity shows how effectively Ever Supreme Bio Technology , Ltd converts resources into returns. At 16.82%, 6712.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6712.TWO's ROE (16.82%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ever Supreme Bio Technology , Ltd's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.